Crucell to Release Fourth Quarter and Full Year 2009 Results on Tuesday February 9, 2010
(Thomson Reuters ONE) - Leiden, The Netherlands (February 2, 2010) - Dutch biopharmaceutical companyCrucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announcedthat it will release its financial results for the fourth quarter and the fullyear 2009 on Tuesday February 9, 2010 at 07:45 Central European Time (CET).At 14:00 Central European Time (CET), Crucell's management will conduct aconference call, which will also be webcast. To participate in the conferencecall, please call one of the following telephone numbers 15 minutes prior to theevent: +44 203 003 2666 for the UK; +1 646 843 4608 for the US; and +3120 794 8426 for the NetherlandsFollowing a presentation of the results, the lines will be opened for a questionand answer session.The live audio webcast can be accessed via the homepage of Crucell's websiteatwww.crucell.com and will be archived and availablefor replay following the event.About CrucellCrucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a globalbiopharmaceutical company focused on research development, production andmarketing of vaccines, proteins and antibodies that prevent and/or treatinfectious diseases. Its vaccines are sold in public and private marketsworldwide. Crucell's core portfolio includes a vaccine against hepatitis B, afully-liquid vaccine against five important childhood diseases and avirosome-adjuvanted vaccine against influenza. Crucell also markets travelvaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccineand the only aluminum-free hepatitis A vaccine on the market. The Company has abroad development pipeline, with several product candidates based on itsuniquePER.C6® production technology. The Company licenses its PER.C6® technologyand other technologies to the biopharmaceutical industry. Important partners andlicensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis,Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, theNetherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden,Switzerland, UK and the USA. The Company employs over 1200 people. For moreinformation, please visit www.crucell.com .This press release contains forward-looking statements that involve inherentrisks and uncertainties. We have identified certain important factors that maycause actual results to differ materially from those contained in suchforward-looking statements. For information relating to these factors pleaserefer to our Form 20-F, as filed with the U.S. Securities and ExchangeCommission on April 22, 2009, in the section entitled 'Risk Factors'. TheCompany prepares its financial statements under International FinancialReporting Standards (IFRS).Financial Calendar 11 May 2010 Q1 Results 2010 4 June 2010 Annual General Meeting of Shareholders 17 August 2010 Q2 Results 2010 9 November 2010 Q3 Results 2010 15 February 2011 Q4 Results 2010For further information please contact:Crucell N.V.Oya YavuzVice PresidentCorporate Communications & Investor RelationsTel. +31-(0)71-519 7064ir(at)crucell.com www.crucell.com [HUG#1379666] PDF file: http://hugin.info/132631/R/1379666/339615.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:Leseranfragen:PresseKontakt / Agentur:Bereitgestellt von Benutzer: hugin
Datum: 02.02.2010 - 08:03 Uhr
Sprache: Deutsch
News-ID 1009904
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Anmerkungen:
Diese Pressemitteilung wurde bisher
118 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Crucell to Release Fourth Quarter and Full Year 2009 Results on Tuesday February 9, 2010
"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V.
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
